Some patients have reported that COVID-19 symptoms recurred after completing treatment and experiencing improvement after Pfizer Inc's PFE COVID-19 oral antiviral treatment Paxlovid.
Pfizer said that from more than 300,000 patients the company is monitoring who received the 5-day treatment, around 1-in-3,000 - about 0.03% - reported a relapse after taking the pills, Reuters reported
This is a lower rate than about 2% of participants who experienced a rebound in viral levels after treatment.
The Pfizer trial suggested relapses may be a broader COVID trend as a similar number of those who had received a placebo also had a rebound in viral load levels.
The cause is not yet known. Some doctors suggest that because the drug attacks the virus so quickly, some patients' immune responses to COVID may be muted, allowing the virus to replicate again.
Others have said there may be a not yet identified common characteristic among those who suffer a rebound. The FDA has also said it is unclear whether rebounds are related to Paxlovid.
Pfizer Chief Development Officer William Pao said it might be related to the virus itself, not Paxlovid since the phenomenon was found among patients who got the drug and those who did not.
The agency also stressed that the rebounds do not change Paxlovid's ability to reduce hospitalization and death.
Price Action: PFE shares closed down by 0.08% at $49.45 on Wednesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.